NRx Pharmaceuticals Reports Q3 Results with EPS Beat and Significant Revenue Growth
NRx Pharmaceuticals (NRXP) reported third-quarter financial results characterized by a significant year-over-year revenue surge of 383.3%, reaching $1.16 million. While this figure slightly missed analyst expectations by $0.13 million, the company's GAAP earnings per share (EPS) of -$0.05 outperformed estimates by $0.16. The results come amid positive regulatory developments for the company, specifically regarding FDA approval for a preservative-free generic ketamine injection. This product is positioned as a key growth driver within the psychiatric treatment market.

Tickers: $NRXP
Topics: earnings_report eps_beat fda_approval revenue_growth